Piramal Pharma Solutions new API Plant in Canada goes online
Mumbai: Piramal Pharma Limited's Pharma Solutions business, a Contract Development and Manufacturing Organization (CDMO), today announced that a new active pharmaceutical ingredient (API) plant at the company's site in Aurora, Ontario, has come online and successfully completed its initial production runs.
The new plant, built as part of a CAD $30 million capital investment in the Aurora site, features more than ten thousand square feet of new manufacturing space and includes two new reactor suites with additional filtration and drying capabilities.
"The plant will support ongoing customer demand for Piramal Pharma Solutions' expertise in APIs and enhances and expands the company's ability to produce clinical to commercial scale APIs including highly potent APIs requiring an Occupational Exposure Limit (OEL) of 1mcg/m3," the company stated.
Since coming online, the plant has successfully implemented programs for clients that include process validation campaign, a registration campaign for clinical re-supply, and an engineering campaign. There is strong customer demand for the new plant's capacity, with a pipeline of clinical and commercial scale projects planned for the future.
Read also: Piramal Enterprise appoints Anita Marangoly George as Independent Director
Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions said, "It's exciting to see the capacity expansion at our Aurora facility in Canada begin to deliver for our clients. We've achieved our objectives of strengthening our presence in Canada, adding API development and commercial support for other geographies such as North America and Europe, and supporting market demand for integrated solutions. As a Patient Centric organization, this is another example of our commitment to serving the patient community and reducing the burden of disease."
With successful inspections by the US FDA, the UK MHRA and the PMDA, Piramal Pharma Solutions' Aurora facility has a stellar track record of regulatory compliance.
Read also: Piramal Pharma signs Amyra Dastur as brand ambassador for Lacto Calamine skin care product range
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.